Vaxcyte, Inc. (PCVX) stock
PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$59.40−2.21 (-3.59%)
Close on Nov 17, 2026Market cap $8.84BP/E –Yield 0.00%
Vaxcyte net income
Net income is the profit left for shareholders after every expense, interest and tax.
Vaxcyte's net income for the twelve months ending Jun 30, 2026 was -$1.06B. For fiscal 2025 it was -$766.63M. The highest annual figure on record is -$29.49M in fiscal 2018.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$766.63M | – |
| FY2024 | Dec 31, 2024 | -$463.93M | – |
| FY2023 | Dec 31, 2023 | -$402.27M | – |
| FY2022 | Dec 31, 2022 | -$223.49M | – |
| FY2021 | Dec 31, 2021 | -$100.08M | – |
| FY2020 | Dec 31, 2020 | -$89.22M | – |
| FY2019 | Dec 31, 2019 | -$50.27M | – |
| FY2018 | Dec 31, 2018 | -$29.49M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$284.30M | – |
| Q1 FY2026 | Mar 31, 2026 | -$320.62M | – |
| Q4 FY2025 | Dec 31, 2025 | -$246.51M | – |
| Q3 FY2025 | Sep 30, 2025 | -$212.83M | – |
| Q2 FY2025 | Jun 30, 2025 | -$166.57M | – |
| Q1 FY2025 | Mar 31, 2025 | -$140.72M | – |
| Q4 FY2024 | Dec 31, 2024 | -$137.08M | – |
| Q3 FY2024 | Sep 30, 2024 | -$103.12M | – |
| Q2 FY2024 | Jun 30, 2024 | -$128.70M | – |
| Q1 FY2024 | Mar 31, 2024 | -$95.02M | – |
| Q4 FY2023 | Dec 31, 2023 | -$180.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$92.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -$68.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$60.46M | – |
| Q4 FY2022 | Dec 31, 2022 | -$78.05M | – |
| Q3 FY2022 | Sep 30, 2022 | -$57.92M | – |
| Q2 FY2022 | Jun 30, 2022 | -$48.53M | – |
| Q1 FY2022 | Mar 31, 2022 | -$38.99M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.56M | – |
| Q3 FY2021 | Sep 30, 2021 | -$26.62M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.68M | – |
| Q1 FY2021 | Mar 31, 2021 | -$21.22M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.74M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$20.32M | – |
| Q1 FY2020 | Mar 31, 2020 | -$27.14M | – |
| Q4 FY2019 | Dec 31, 2019 | -$14.62M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.32M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.67M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.67M | – |
See a number that looks wrong?